Yasuaki Arai, director of the National Cancer Center Hospital, Tokyo, Japan, and current president of the Japanese Society of Interventional Radiology (JSIR), delivered the Honorary Lecture at the European Conference of Interventional Oncology (ECIO) in Nice, France, yesterday. He spoke on the topic “Beyond the evidence—the true goal of interventional oncology” and received a standing ovation for his presentation.
Teleflex will showcase a wide array of products for minimally invasive interventional applications at the 6th European Conference of Interventional Oncology (ECIO) in Nice, France, from 22–25 April 2015.
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSII) (CSI), announced today that it has received FDA clearance for the new 4 French (4 Fr) 1.25 Solid Diamondback 360® Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD).
LOWELL, Mass.--(Healthcare Sales & Marketing Network)--Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions, announced that the Alcyone MEMS Cannula (AMC™), a neuro-ventricular cannula, has received FDA clearance. The AMC is a dual-lumen, MRI-compatible injection and aspiration cannula for use in the brain. The AMC is not intended for implant, and it is intended for single patient use only.
BALTIMORE, April 23, 2015 -- (Healthcare Sales & Marketing Network) -- Clear Guide Medical announces that its first clinical product, the Clear Guide ONE, has received the CE Mark from its Notified Body. The CE Mark allows the marketing and sale of the medical device in 28 Member States of the European Union, as well as Iceland, Norway, Liechtenstein, Switzerland and Turkey. Jack Kent, Director of Regulatory Affairs and Quality System, elaborated on the CE Mark´s importance: "This certification will open global commercialization opportunities in other regions that leverage the CE Mark as a basis for regulatory review. We are currently seeking marketing authorizations in Australia and New Zealand, and we expect to expand to other countries and regions as soon as possible."
Early Experimental and Clinical Experience with a Focal Implant (Tack Endovascular System) for Lower Extremity Post-Angioplasty Dissection Suggests a Safe and Feasible Alternative Treatment
TEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)--Mitralign today highlighted a presentation by Prof. Dr. med. J. Schofer of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg at the recent American College of Cardiology (ACC) Scientific Sessions detailing his experience with the Mitralign Transcatheter Annuloplasty System. At ACC, Schofer discussed his successful use of the Mitralign System to perform a direct transcatheter annuloplasty on special access patients with tricuspid regurgitation (TR). The Mitralign system is not approved for sale or distribution however, it is currently being evaluated in clinical trials for an indication in functional mitral regurgitation.
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif., April 1, 2015 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and sells minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract. The deal is expected to close this week.
BOSTON, April 15, 2015 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced the completion of its sales restructuring program which began on January 4, 2015. The restructuring was implemented to conserve capital and to align the organization to a new commercial strategy built on third party distribution partners. Reflecting some impact from the transition, as well as the trend towards drug eluting stent use in STEMI patients discussed during our fourth quarter 2014 earnings call last month, total revenues for the first quarter 2015 were approximately $500,000, down sequentially from $850,000 in the fourth quarter 2014.
Inari Medical has treated the first patient with its FlowTriever infusion aspiration system. The FlowTriever system received 510(k) marketing clearance from the US Food and Drug Administration (FDA) in February to treat emboli in the peripheral vasculature.
CryoLife has provided an update on its ongoing litigation with CR Bard and some of its subsidiaries regarding PerClot. The US District Court for the District of Delaware has allowed CryoLife’s declaratory judgement lawsuit against CR Bard’s Medafor subsidiary to proceed. The court also granted Medafor’s motion for a preliminary injunction with respect to CryoLife’s marketing and sale of PerClot Topical in the USA. CryoLife is currently awaiting the court’s order, which it expects will provide details regarding the scope of the injunction.
ArtVentive Medical has announced the first use of its Endoluminal Occlusion System (EOS) in the USA at The Johns Hopkins Hospital in Baltimore, where Kelvin Hong and Anobel Tamrazi performed a splenic artery occlusion using the device.
At the Leipzig Interventional Course (LINC, 27–30 January, Leipzig, Germany), Michael Lichtenberg, chief of the Vascular Center Klinikum Arnsberg, Arnsberg, Germany, presented information about a new balloon dilatation catheter that allows a targeted injection of fluids during percutaneous transluminal angioplasty.
ClearFlow is currently exhibiting its PleuraFlow Active Clearance Technology system at the 34th annual Association of Physician Assistants in Cardiovascular Surgery (APACVS) meeting (1–4 March, Las Vegas, USA). PleuraFlow will also be displayed at the Maquet Medical Systems USA booth until 4 March. Maquet is the exclusive distributor of ClearFlow’s PleuraFlow system in the USA.
Cardinal Health announced on 2 March 2015 plans to acquire Johnson & Johnson’s Cordis business, a global manufacturer of cardiology and endovascular devices, for US$1.944 billion in cash, or approximately US$1.594 billion, net of the present value of tax benefits.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos